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COMMERCIALIZING AGRICULTURAL 
BIOTECHNOLOGY
Some time ago I decided that every time I hear Jerry Caulder speak, I 
would remember and try to use one of his quotations. I think it appropri-
ate to repeat his quote from Will Rogers: “It’s 
not what we don’t know that hurts us, it’s what 
we know that ain’t true that’s gonna kill us in 
the end”(sic). As we talk about the real risks 
and rewards in biotechnology, it behooves us to 
remember those words.
I will address the impediments to industrializa-
tion and commercialization of agricultural 
biotechnology. One of the goals of the meeting 
was to assess “the reasons why many biotech-
nology innovations have failed to develop as 
predicted.” Well, I would dispute that view. 
Biotechnology innovations have come almost exactly in line with what 
responsible and knowledgeable people involved in this field since the late 
1970s and early 1980s have predicted. For instance in the early 1980s, Mar-
tin Apple, president of International Plant Research Institute, was widely 
quoted—whether accurately or inaccurately—predicting plant biotech-
nology would generate pork chops on trees. If that is the standard as to 
our progress, obviously we are not there. On the other hand, Tom Urban, 
president of Pioneer-Hi Bred, the largest seed company in the world and 
one of the more knowledgeable individuals in this field, still predicts we 
will not have genetically engineered plant products on the market and 
making an impact until the year 2000. In many respects, Tom Urban is as 
wrong as Martin Apple was as to what is going to happen. We are on the verge 
of having a whole plethora of products that are going to have material, eco-
nomic and positive environmental impacts on the agricultural arena.
Let me comment on a few of the specific barriers to commercialization 
and the standing of a few specific products in the regulatory process. Ear-
lier in this volume (p. I l l ) ,  Bob Nicholas presented the regulatory back-
ground. I will comment on where we stand in the process, using examples
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from Calgene, my own company, because those are the most familiar 
ones. To date, the U. S. Department of Agriculture (USDA) has issued 
over 120 permits to conduct field trials with genetically engineered plants. 
Calgene was the first company to get such an approval in November, 1987, 
and has since received over 20 such permits. The average time from the 
day we file with the USDA until we get those approvals is 105 days. That is 
very reasonable in the context of any federal bureaucracy, particularly the 
regulatory ones. Calgene’s most recent field trial represents work we are 
doing in genetically engineered cotton which is in the third year of field 
trials. Under a single permit, we received approval to conduct 34 trials in 
12 different states. All of those trials were planted as of the last Friday in 
May, despite the highest amount of rain in the southern U.S. since Noah 
built the ark. Those trials will generate data that will not only answer the ques-
tions of the safety of the plants themselves, but that data will be shared with re-
sponsible researchers in various university systems and within the Food and 
Drug Administration (FDA) itself. That data will allow the USDA and other 
regulatory agencies to make appropriate determinations of risks, if any, in go-
ing to full commercialization of those types of plants.
The FDA has taken a lot of criticism, and I feel those criticisms are com-
pletely unfounded and inappropriate. In fact, FDA has moved forward 
with this type of technology assessment. Before FDA can decide what 
regulations they want to issue, they need to review specific data, under-
stand what is involved and what changes really occur in plants. They have 
to review information that has been generated and that is happening. 
Calgene filed a petition for the use of a selectable marker and vector in No-
vember 1990, asking FDA to review the safety of 80 percent of the plasmid 
rather than just a specific target gene, in order to separate the issues. There 
are lots of different ways to file data with FDA, but Calgene specifically se-
lected the advisory opinion route because it is a public process that invites 
public comment, and because every single piece of data Calgene submitted to 
FDA is public. Anyone that wants it can have it, either from Calgene or FDA.
In fact on May 1,1991, in the Federal Register, the FDA published a re-
quest for public comment. Calgene entered the 90-day period for com-
ments on the safety of the use of the technology. I encourage all of you that 
have an abiding interest in this to comment. Comments are exactly what 
FDA wants, and part of this whole process is getting public input. I hope 
all of you will avail yourselves of that opportunity—the comment period
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closes on July 30. My strong understanding and belief is that FDA will, on 
the basis of the focused thinking they have done on this topic now, issue 
some specific guidelines or points to consider. I do not know what the ex-
act format will be, but I expect a decision from FDA before the end of 
1991.1 believe you will see FDA making a positive determination on the 
safety of genetically engineered whole foods in the calendar year 1992-a 
forecast I am totally prepared to stick with.
Next let me comment on agency collaboration-one of the issues in the 
public arena where people like to stir up trouble. There is the impression 
that massive gang warfare is going on between various agencies back in 
Washington, which is not true (with one notable exception that I will 
avoid). Certainly, in my mind, the collaboration between FDA and USDA 
is excellent. For the last five years, numerous meetings have convinced me that 
FDA has the technical competency through all of their various Centers of Food 
Safety, Center for Veterinary Medicine and various departments of toxicologists 
and physiologists, to make the scientific assessments necessary to assure the 
American people that this technology is not only safe but is beneficial.
Let us focus on the major structural impediments to agricultural 
biotechnology. First and foremost is the nature of the science. There is not 
a single plant biotechnology product to date that has been delayed by the 
regulatory process. Plant products have been delayed by the nature of the 
science involved, the inherent difficulty and the time required to work 
with plants. I would not make the same statement with microbes, but I as-
sert that with plants, you are talking about both recalcitrant and slow 
moving science. For example, if you are going to genetically engineer a to-
mato, the shortest period of time that you can take is about six weeks. And 
that just gets you to the plantlet. You must still grow the plant, get the 
seeds and harvest the seeds to determine whether you have affected the re-
productive capacity of the plant. Thus, the science is the principal prob-
lem. It takes a long time. You can only do one experiment a year. You 
transform a plant, grow it up and get the results a year later, which tends to 
make progress move rather slowly. The inherent nature of the science and 
the fact that you are dealing with the plants is an impediment. A second 
impediment is the whole base of knowledge in this field. Previous speakers 
have talked about it and the small allocations from the federal research 
budget is yet another impediment. Federal research spending in the plant
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sciences or agricultural sciences is miniscule. It does not even make the 
chart compared to the money that has been historically, and is currently, 
piled into biomedical research. Jerry Caulder estimated that two percent 
of the total federal research budget goes into agricultural science as 
broadly defined. Another measure to consider: historically, the National 
Institute of Health (NIH) has poured approximately three billion dollars a 
year into research in the human area. In contrast, over three years ago my 
good friend Paul Stumpf, who heads the competitive grants program at 
the USDA, was talking about a $15 million budget in terms of competitive 
grants. Now it is $75 million. That is still a drop in the bucket compared to 
what is being spent in the development of basic knowledge in other areas. 
Just to give you an idea of the parameters, I calculated that private indus-
try in the U.S. invests $350 million a year on plant biotechnology research. 
That is a substantial figure, although again it is not relative to the base of 
knowledge that we have and need to know. Calgene spends about $12 mil-
lion a year and has invested $75 million in research in this area in the last 
ten years. The nature of the science and level of knowledge are major bar-
riers to accelerated progress.
A third major barrier to commercialization and to making an impact 
with this technology is finance. It is damn tough to raise money in any ag-
ricultural enterprise in the U.S. for several reasons, not the least of which 
is that there is no major business school that serves as a breeding ground 
for all the investment bankers and the financial analysts in the U.S. Virtu-
ally no business schools has courses with agribusiness in the title, let alone 
agribusiness in the curriculum. So the financial decision makers in this 
country are totally ignorant of the underlying economics and opportuni-
ties presented by the largest single industry in the country. That is why 
when you go to a Wall Street banker and say, “I’ve got a great ag/biotech 
idea and need money”, they just sort of stare out the window and look at 
the clouds because they do not understand anything about it. It is too 
difficult for them to take time to learn—they would much rather find a 
guy who has got a cure for AIDS. Then they would say, “Great, I’ll finance 
it. Don’t give me any details. It sounds great. Go for it.” There is a huge 
knowledge gap out there.
Some finance problems are related to frustrations stemming from a fail-
ure to meet expectations. Agricultural biotechnology is highly visible.
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Typically, the kinds of products we are talking about here and that other com-
panies in the industry are talking about have been developed in the bowels of 
large corporate research groups where they have had a ten year gestation period 
before seeing the public light. Now what has happened is that the only way 
companies such as Calgene and other agricultural biotechnology companies 
could raise money to do research was to go public with the prospects of what 
they were doing at a very, very early stage. People saw for the very first time how 
truly difficult and long-term science is. Historically, the development of a drug 
has never become visible to the public until it is in a phase three clinical or has 
actually been approved. What the public does not see is the ten years required to 
move a drug along and get it to clinical trials. Public visibility is a cross that we 
have to bear, a fact of life which increases the difficulty of financing.
I will make a prediction—that there will be no more agricultural bio-
technology start ups in this country in the foreseeable future, because it 
will be impossible to finance them. There are only about half a dozen suc-
cessful agricultural biotechnology companies at the present time, and I 
predict at least half of those will be out of business or be acquired by for-
eign companies within the next two years. That is a particularly chilling 
message. While lots of people in the U.S. are running around worrying 
about the demise of the small family farm (which is a socioeconomic 
phenomenon that is going to happen irrespective of technology) they fail 
to realize that nine of the top ten or twelve companies, representing over 
90 percent of the agrichemical sales in this country, are owned by foreign 
corporations. Three of the top five seed companies are owned by foreign 
corporations. If you are worried about a narrow-minded, inward-looking 
and self-perpetuating focus of technology, there is no better way to have it 
happen than to have all of your inputs controlled by mega corporations 
that do not have their roots in this country. People need to start learning a 
little bit about financing and fostering innovation—instead of stifling it. 
Otherwise we face some very chilling prospects.
The next issue is the whole convoluted structural situation in interna-
tional agriculture-the common agricultural policy in Europe, the Farm 
Bill here. The structural situation here unequivocally discriminates 
against innovation. New practices are discriminated against, because of 
the existing political and financial structure. Canola is a good example. 
Canola is a new crop in the U.S. there are 40 million acres are grown else-
where in the world, but it is new to the U.S. It is easy to show that canola 
grown in the winter is the only crop which you can introduce as a diver-
sion crop for crop rotation. It is the only alternative to winter wheat in 
huge portions of the U.S. Even with the new, non-proven varieties we 
have, you can show unequivocally that a canola farmer can generate $30 to 
$50 an acre more profit growing canola than he can growing winter wheat. 
But the Farm Bill gives farmers a $40 per acre subsidy and takes away any 
incentive for the farmer to innovate. Farmers say “I don’t care, why should 
I innovate?” This is a very serious structural problem. We are making a 
little bit of headway; the 1990 Farm Bill provides a little more flexibility 
and that is helpful. But we still have a long way to go.
The final impediment is public acceptance. I echo Walter Truett 
Anderson’s final point — we must learn from experience. Rather than re-
flecting on the Nataufians’ experience as Walter did, I thought about our 
experience with fruit flies {Drosophila). Last week, in the Wall Street Jour-
nal there was a front page article on Drosophila research being undertaken 
by William Quinn at Massachusetts Institute of Technology. Quinn is par-
ticularly interested in fruit flies because the molecular and genetic struc-
ture of the Drosophila brain is very similar to the human brain. There are 
lots of parallels and it has been discovered that the fruit fly has developed a 
learned response. The lowly fruit fly can learn from experience. However, 
Dr. Quinn is studying a particular mutant group who cannot do so. I 
would place many of the adamant opponents of agricultural biotechnol-
ogy in the category of the abnormal fly that Dr. Quinn is looking at, be-
cause they simply seem unable to learn from experience. We have had 15 
years of successful research and of research expansion without a single 
person in the U.S. getting ill from this technology. That is a safety record 
unmatched by any other industry in the history of the world. Even in the 
wheelbarrow industry, I am sure a falling wheelbarrow killed someone. 
People have to put this safety record into perspective. The reason we are 
doing field trials is to learn. We are generating data that allows us to move 
forward without worrying that the sky is going to fall on us. I think we all 
should keep that in mind and move forward aggressively to truly reap the 
harvest of this great technology.
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